Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug–drug interaction study in liver transplant recipients
Therapeutic Advances in Drug Safety
Published online on February 12, 2026
Abstract
Therapeutic Advances in Drug Safety, Volume 17, January-December 2026.
Background:While recipient cytochrome P450 (CYP) genetic polymorphisms are established modulators of tacrolimus (TAC) pharmacokinetics, the combined effects of donor-derived hepatic and recipient intestinalCYP3A4/5andCYP2C19genotypes during ...
Background:While recipient cytochrome P450 (CYP) genetic polymorphisms are established modulators of tacrolimus (TAC) pharmacokinetics, the combined effects of donor-derived hepatic and recipient intestinalCYP3A4/5andCYP2C19genotypes during ...